|
|
Tepnel Extends License Agreement with Luminex
Tepnel Life Sciences plc ('Tepnel' or 'the Company')
Tepnel Life Sciences PLC (AIM: TED), the international Molecular Diagnostics and Research Products & Services group, announces it has agreed to an extension of the license with Luminex Corporation (NASDAQ: LMNX) for access to the Luminex® xMAP® platform. The Luminex xMAP
technology is incorporated into Tepnel’s innovative molecular diagnostics products.
Tepnel’s LifeMatch products are used for the measurement and detection of HLA (Human Leukocyte Antigen) markers which are used in both bone marrow and solid organ transplantation. These products allow the rapid analysis of a donor’s HLA type to determine if they are a potential match for the patient waiting for a bone marrow transplantation or a patient on a solid organ waiting list.
Tepnel develops highly multiplexed DNA and protein based assays and user friendly software for its highly successful LifeMatch product line. The Luminex technology allows Tepnel Lifecodes’ customers to analyze up to 100 simultaneous reactions on a single patient’s sample in a user friendly, cost effective manner with minimal hands-on time.
Tepnel’s CEO Ben Matzilevich commented ‘We are pleased to extend our agreement for the use of Luminex’s xMAP technology for our Molecular Diagnostics Division. The xMAP technology provides a powerful platform when combined with our state-of-the-art LifeMatch family of Lifecodes assays and software. We continue to extend our leadership position in the field of organ transplantation and anticipate strong continued growth for the LifeMatch product lines.”
Luminex Corporation President and CEO Patrick Balthrop stated, "Customers in the HLA market have led the way toward improving efficiency of diagnostic testing through multiplexing. HLA customers have rapidly converted standard protein-based ELISA tests to multiplexed tests based on xMAP technology. Additionally, these same customers take advantage of the flexibility of xMAP technology by also testing nucleic acids, where up to 100 different markers per sample are analyzed routinely. We are pleased to continue working with Tepnel Lifecodes to deliver multiplexed solutions in the HLA market and continue to be enthusiastic about xMAP’s ability to satisfy the increasing performance demands of our partners and customers."
Tepnel’s LifeMatch product line is rapidly gaining market share in the USA, Europe and ROW. In January of this year, Tepnel extended the LifeMatch product lines with two new product offerings, LSA™ and DSA™. LSA is a highly multiplexed assay system consisting of more than 150 cloned recombinant proteins. This assay allows clinicians to accurately identify permissible allele level antigens in highly sensitized patients in order to minimize the chance of rejection and ensure a better outcome. The DSA product line allows clinicians to screen the patient for the presence of antibodies against HLA antigens of the donor ensuring compatibility and minimizing rejection. Tepnel Lifecodes will continue to expand its product lines in order to meet the needs of the transplant community.
-End-
For Further Information:
Tepnel Life Sciences plc
Ben Matzilevich, CEO
Carol Smith
Tel: 0161 946 2200
Capital MS&L
Mary Clark or Catie Corcoran
Tel: +44 20 7307 5330
Email: mary.clark@capitalmsl.com
Notes to Editors
About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with 195 employees. TLS provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The company’s strategy has been to identify high growth niche opportunities within these multi-billion pound markets. TLS focuses on these niche opportunities with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments.
|
|
|
